Autolus Therapeutics/$AUTL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Autolus Therapeutics
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
Ticker
$AUTL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
649
ISIN
US05280R1005
Website
AUTL Metrics
BasicAdvanced
$615M
-
-$0.89
1.76
-
Price and volume
Market cap
$615M
Beta
1.76
52-week high
$2.43
52-week low
$1.11
Average daily volume
2.3M
Financial strength
Current ratio
9.244
Quick ratio
7.755
Long term debt to equity
83.041
Total debt to equity
83.842
Interest coverage (TTM)
-13.75%
Profitability
EBITDA (TTM)
-259.082
Gross margin (TTM)
-1,620.50%
Net profit margin (TTM)
-2,642.69%
Operating margin (TTM)
-2,966.03%
Effective tax rate (TTM)
-1.60%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-20.27%
Return on equity (TTM)
-49.97%
Valuation
Price to revenue (TTM)
68.23
Price to book
1.66
Price to tangible book (TTM)
1.71
Price to free cash flow (TTM)
-2.166
Free cash flow yield (TTM)
-46.17%
Free cash flow per share (TTM)
-106.65%
Growth
Revenue change (TTM)
-14.16%
Earnings per share change (TTM)
-24.77%
3-year revenue growth (CAGR)
59.35%
3-year earnings per share growth (CAGR)
-21.39%
Bulls say / Bears say
Autolus Therapeutics' Aucatzyl product is expected to begin its market ascent in the first half of 2025, with a more robust sales increase anticipated in the second half, indicating strong future revenue potential. (Investing.com)
The company maintains a strong financial position with more cash than debt, providing a solid foundation for ongoing research and development activities. (Investing.com)
Analysts project significant revenue growth of 169% for FY2025, reflecting confidence in the company's future performance. (Investing.com)
Truist Securities adjusted its outlook on Autolus, reducing the price target to $10.00 from $11.00, reflecting a refinement in the firm's financial model and projections for the AUTO4 program. (Investing.com)
Wells Fargo & Company decreased their price objective on Autolus Therapeutics from $8.00 to $6.00, indicating a more cautious outlook on the stock. (The AM Reporter)
Autolus reported a net loss of $220.7 million for the fourth quarter of 2024, up from $208.4 million the previous year, highlighting ongoing financial challenges. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
AUTL News
AllArticlesVideos
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
GlobeNewsWire·3 weeks ago
Autolus Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewsWire·1 month ago
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Autolus Therapeutics stock?
Autolus Therapeutics (AUTL) has a market cap of $615M as of June 30, 2025.
What is the P/E ratio for Autolus Therapeutics stock?
The price to earnings (P/E) ratio for Autolus Therapeutics (AUTL) stock is 0 as of June 30, 2025.
Does Autolus Therapeutics stock pay dividends?
No, Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Autolus Therapeutics dividend payment date?
Autolus Therapeutics (AUTL) stock does not pay dividends to its shareholders.
What is the beta indicator for Autolus Therapeutics?
Autolus Therapeutics (AUTL) has a beta rating of 1.76. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.